What is the 13F Pro Quality Score for HAE?

13F Pro ranks HAEMONETICS CORP (HAE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HAE's current score at https://13fpro.ai/company/HAE (free sign-up required for the full ranking).

Where does 13F Pro source HAE data?

All HAEMONETICS CORP fundamentals and ownership data come directly from SEC EDGAR. HAEMONETICS CORP files with the SEC under CIK 313143. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HAE in?

HAEMONETICS CORP (HAE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HAE research updated on 13F Pro?

HAE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HAEMONETICS CORP(HAE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 313143 HAE stock profile & AI dashboard →

13F Pro Quality Score

51.4/100

Rank #1,531 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

26.5/100

Profitability

40.8/100

Balance Sheet

65.1/100

Earnings Quality

91.7/100

Free Cash Flow

74.8/100

Institutional Flow

30.9/100

Revenue Scale

55.8/100

Dilution Risk

36.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why HAE Scores 51/100

exact factor attribution · 2026-09-11

HAE's composite is driven by earnings quality and free cash flow, held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+4.2 pts

92th pct

Free cash flow

+3.7 pts

75th pct

Capital efficiency

+1.5 pts

65th pct

Scale

+0.9 pts

56th pct

Shareholder dilution

-0.7 pts

36th pct

Institutional flow

-1.0 pts

31th pct

Earnings growth

-1.2 pts

27th pct

Profitability

-1.4 pts

41th pct

Revenue growth

-4.7 pts

27th pct

Latest change (2026-08-06): 61 → 58 · ↓ Free cash flow 76→65; ↓ Revenue growth 42→33

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

HAE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for HAEMONETICS CORP (HAE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HAE at 51.4/100 on a 32-signal composite quality model, placing it at rank #1,531 of 2,961 stocks — the bottom half of the AI-ranked universe. HAE scores in the top quartile across earnings quality (91.7). Areas of concern include revenue growth (26.5) and institutional flow (30.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HAEMONETICS CORP reports quarterly revenue of $339.4M, net income of $33.0M, free cash flow of $44.4M. Top institutional holders of HAE by reported 13-F value include BlackRock, Neuberger Berman Group, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HAE trades on the NYSE exchange and files with the SEC under CIK 313143. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HAE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HAEMONETICS CORP directly from SEC EDGAR. HAEMONETICS CORP's 13F Pro composite quality score has ranged between 47 and 66 since 2024, currently 51.4 — a declining long-term trajectory across 55 quarterly and live scoring snapshots.

✦

Fun facts about HAEMONETICS CORP

Quirks, history, and lore behind HAE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical technology company · mid-cap · listed on NYSE · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of $1 billion, with operations spanning more than 80 countries — not a household name, but hospitals worldwide depend on it.
3
The History
Founded in the 1970s, it grew by solving a very specific problem: how do you efficiently collect, separate, and process human blood outside the body?
4
The Secret
Its core business is blood management technology — machines and disposables that separate whole blood into its components so nothing goes to waste.
5
The Lore
It is a dominant player in apheresis — the process of drawing blood, harvesting a specific component like platelets or plasma, and returning the rest to the donor. Blood banks love it.
6
The Giveaway
Its name literally means "blood mechanics" in Greek, and its ticker HAE is about as on-the-nose as corporate branding gets.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$339.4M

Net Income

Q2 2026

$33.0M

Free Cash Flow

Q2 2026

$44.4M

ROIC

Q2 2026

11.3%

D/E Ratio

Q2 2026

1.43

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-2.0% YoY

$1.33BFY 2026

FY23 $1.17BFY24 $1.31BFY25 $1.36BFY26 $1.33B

Net Income

-42.0% YoY

$97.3MFY 2026

FY23 $115.4MFY24 $117.6MFY25 $167.7MFY26 $97.3M

Operating Income

-29.3% YoY

$156.7MFY 2026

FY23 $156.0MFY24 $164.9MFY25 $221.8MFY26 $156.7M

EPS (Diluted)

-38.1% YoY

$2.05FY 2026

FY23 $2.24FY24 $2.29FY25 $3.31FY26 $2.05

Total Assets

-2.2% YoY

$2.40BFY 2026

FY23 $1.93BFY24 $2.20BFY25 $2.45BFY26 $2.40B

Total Debt

-18.6% YoY

$1.24BFY 2026

FY23 $765.9MFY24 $807.8MFY25 $1.53BFY26 $1.24B

Op. Cash Flow

+61.4% YoY

$293.2MFY 2026

FY23 $273.1MFY24 $181.8MFY25 $181.7MFY26 $293.2M

Free Cash Flow

+82.8% YoY

$260.4MFY 2026

FY23 $81.7MFY24 $143.6MFY25 $142.4MFY26 $260.4M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.33B -2.0%	$1.36B +4.0%	$1.31B +12.0%	$1.17B +17.7%	$993.2M +14.1%	$870.5M
Net Income	$97.3M -42.0%	$167.7M +42.6%	$117.6M +1.9%	$115.4M +166.1%	$43.4M -45.4%	$79.5M
Operating Income	$156.7M -29.3%	$221.8M +34.5%	$164.9M +5.7%	$156.0M +93.2%	$80.8M -10.0%	$89.7M
EPS (Diluted)	$2.05 -38.1%	$3.31 +44.5%	$2.29 +2.2%	$2.24 +166.7%	$0.84 -45.8%	$1.55
Total Assets	$2.40B -2.2%	$2.45B +11.6%	$2.20B +13.5%	$1.93B +4.0%	$1.86B +2.2%	$1.82B
Total Debt	$1.24B -18.6%	$1.53B +89.2%	$807.8M +5.5%	$765.9M -1.0%	$773.6M +9.3%	$707.6M
Operating Cash Flow	$293.2M +61.4%	$181.7M -0.0%	$181.8M -33.4%	$273.1M +58.5%	$172.3M +58.3%	$108.8M
Free Cash Flow	$260.4M +82.8%	$142.4M -0.8%	$143.6M +75.7%	$81.7M +7.9%	$75.8M +5.6%	$71.8M

Get alerted when HAE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HAEMONETICS CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HAE

BlackRock, Inc.
$443.2M5,909,258 sh
Neuberger Berman Group LLC
$313.5M4,179,443 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$191.0M2,546,394 sh
LINDEN ADVISORS LP
$179.2M176,911,000 sh
AQR CAPITAL MANAGEMENT LLC
$165.0M2,266,489 sh
ARIEL INVESTMENTS, LLC
$154.6M2,060,966 sh
VANGUARD CAPITAL MANAGEMENT LLC
$154.5M2,059,578 sh
STATE STREET CORP
$136.4M1,818,186 sh
DIMENSIONAL FUND ADVISORS LP
$118.9M1,585,222 sh
CITADEL ADVISORS LLC
$113.3M1,510,120 sh

Fund	Value	Shares
BlackRock, Inc.	$443.2M	5,909,258
Neuberger Berman Group LLC	$313.5M	4,179,443
VANGUARD PORTFOLIO MANAGEMENT LLC	$191.0M	2,546,394
LINDEN ADVISORS LP	$179.2M	176,911,000
AQR CAPITAL MANAGEMENT LLC	$165.0M	2,266,489
ARIEL INVESTMENTS, LLC	$154.6M	2,060,966
VANGUARD CAPITAL MANAGEMENT LLC	$154.5M	2,059,578
STATE STREET CORP	$136.4M	1,818,186
DIMENSIONAL FUND ADVISORS LP	$118.9M	1,585,222
CITADEL ADVISORS LLC	$113.3M	1,510,120

Companies Similar to HAE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

NVST

Envista Holdings Corp

AI score

Similar quality profile · 26 shared holders

ARIEL INVESTMENTS, LLC Boston Partners Wellesley Asset Management

LNTH

Lantheus Holdings, Inc.

AI score

Similar quality profile · 27 shared holders

Holocene Advisors, LP Boston Partners SILVERCREST ASSET MANAGEMENT GROUP LLC

PBH

Prestige Consumer Healthcare Inc.

AI score

Similar quality profile · 17 shared holders

ARIEL INVESTMENTS, LLC Boston Trust Walden Corp SILVERCREST ASSET MANAGEMENT GROUP LLC

RGEN

REPLIGEN CORP

AI score

Similar quality profile · 26 shared holders

T. Rowe Price Investment Management, Inc.Holocene Advisors, LP SILVERCREST ASSET MANAGEMENT GROUP LLC

PCRX

Pacira BioSciences, Inc.

AI score

Similar quality profile · 12 shared holders

LINDEN ADVISORS LP Wellesley Asset Management Calamos Advisors LLC

CNMD

CONMED Corp

AI score

Similar quality profile · 10 shared holders

Invenomic Capital Management LP SILVERCREST ASSET MANAGEMENT GROUP LLC Calamos Advisors LLC

Pediatrix Medical Group, Inc.

AI score

Similar quality profile · 14 shared holders

SILVERCREST ASSET MANAGEMENT GROUP LLC Aristotle Capital Boston, LLC NORDEA INVESTMENT MANAGEMENT AB

AMPH

Amphastar Pharmaceuticals, Inc.

AI score

Similar quality profile · 5 shared holders

ROYCE & ASSOCIATES LP NORDEA INVESTMENT MANAGEMENT AB Legato Capital Management LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HAE on your watchlist

Track score changes the day HAEMONETICS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HAE a good stock to buy?

13F Pro's AI-powered analysis of HAEMONETICS CORP (HAE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HAE are available on the HAE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HAE is classified as a mid company.

Which hedge funds own HAE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HAE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HAEMONETICS CORP's investment landscape.